HC Wainwright Expects Higher Earnings for Benitec Biopharma

Benitec Biopharma Limited (NASDAQ:BNTC) – Analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Benitec Biopharma in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.25) per share for the quarter, up from their previous estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.97) EPS and FY2027 earnings at ($1.41) EPS.

A number of other research firms have also commented on BNTC. Zacks Research raised shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Wall Street Zen cut shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, January 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.67.

Benitec Biopharma Stock Down 2.8%

Shares of BNTC stock opened at $10.60 on Thursday. The stock has a 50-day simple moving average of $11.82 and a 200 day simple moving average of $13.05. The stock has a market capitalization of $364.11 million, a P/E ratio of -9.30 and a beta of 0.31. Benitec Biopharma has a fifty-two week low of $9.85 and a fifty-two week high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03).

Hedge Funds Weigh In On Benitec Biopharma

Several large investors have recently modified their holdings of the stock. AWM Investment Company Inc. raised its stake in Benitec Biopharma by 54.7% in the 4th quarter. AWM Investment Company Inc. now owns 282,977 shares of the biotechnology company’s stock worth $3,812,000 after purchasing an additional 100,000 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Benitec Biopharma in the fourth quarter worth approximately $8,259,000. Marshall Wace LLP acquired a new position in Benitec Biopharma in the fourth quarter valued at $481,000. Barclays PLC boosted its position in shares of Benitec Biopharma by 9.1% during the 4th quarter. Barclays PLC now owns 23,211 shares of the biotechnology company’s stock valued at $313,000 after purchasing an additional 1,928 shares in the last quarter. Finally, Truvestments Capital LLC boosted its holdings in shares of Benitec Biopharma by 156.5% during the 4th quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,339 shares in the last quarter. 52.19% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L bought 77,387 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were acquired at an average price of $13.44 per share, for a total transaction of $1,040,081.28. Following the completion of the acquisition, the director owned 9,700,195 shares of the company’s stock, valued at approximately $130,370,620.80. The trade was a 0.80% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have bought 190,364 shares of company stock worth $2,442,105. Insiders own 4.80% of the company’s stock.

Trending Headlines about Benitec Biopharma

Here are the key news stories impacting Benitec Biopharma this week:

• Positive Sentiment: HC Wainwright raised several near‑term and multi‑year EPS estimates (Q3/Q4 FY2026 and FY2026/FY2027) and reiterated a “Buy” rating with a $32 price target — the firm now models slightly smaller losses, which is a positive sentiment signal for the stock. HC Wainwright note on BNTC
• Neutral Sentiment: Reported short‑interest data show “0” shares and days‑to‑cover of 0.0, which appears to be a data anomaly or reflects no meaningful reported short position — this item is unlikely to move the stock materially on its own.
• Negative Sentiment: Benitec missed most recent reported quarterly EPS (reported -$0.26 vs. -$0.23 expected), and consensus full‑year EPS remains negative (around -$1.48), keeping pressure on the share price despite analyst model tweaks. Recent earnings and stock data for BNTC

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.